Braxia Scientific Corp.
BRAXF
$0.001
-$0.0002-16.67%
| Weiss Ratings | BRAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | BRAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | BRAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.93 | |||
| Price History | BRAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -66.67% | |||
| 30-Day Total Return | -33.33% | |||
| 60-Day Total Return | -62.96% | |||
| 90-Day Total Return | -68.75% | |||
| Year to Date Total Return | -33.33% | |||
| 1-Year Total Return | -86.30% | |||
| 2-Year Total Return | -97.56% | |||
| 3-Year Total Return | -97.40% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -86.36% | |||
| 52-Week Low % Change | 1,100.00% | |||
| Price | BRAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.01 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Mar 05, 2025 | |||
| 52-Week High Price (Date) | Mar 13, 2024 | |||
| Valuation | BRAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 982.87K | |||
| Enterprise Value | 1.34M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.03 | |||
| Earnings Per Share Growth | -38.26% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.19 | |||
| Price/Book (Q) | -1.09 | |||
| Enterprise Value/Revenue (TTM) | 0.82 | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -0.49 | |||
| Enterprise Value/EBIT | -0.45 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | BRAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 263.71M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | BRAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 416-430-9619 | |||
| Address | 700 Bay Street Toronto, ON M5G 1Z6 | |||
| Website | braxiascientific.com | |||
| Country | Canada | |||
| Year Founded | -- | |||
| Profitability | BRAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -179.68% | |||
| Profit Margin | -435.23% | |||
| Management Effectiveness | BRAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -42.23% | |||
| Return on Equity | -- | |||
| Income Statement | BRAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 1.64M | |||
| Total Revenue (TTM) | 1.64M | |||
| Revenue Per Share | $0.01 | |||
| Gross Profit (TTM) | 240.50K | |||
| EBITDA (TTM) | -2.73M | |||
| EBIT (TTM) | -2.94M | |||
| Net Income (TTM) | -7.13M | |||
| Net Income Avl. to Common (TTM) | -7.13M | |||
| Total Revenue Growth (Q YOY) | 0.50% | |||
| Earnings Growth (Q YOY) | 58.31% | |||
| EPS Diluted (TTM) | -0.03 | |||
| EPS Diluted Growth (Q YOY) | 62.12% | |||
| Balance Sheet | BRAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 97.20K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 300.70K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -277.00K | |||
| Current Ratio (Q) | 0.180 | |||
| Book Value Per Share (Q) | $0.00 | |||
| Total Assets (Q) | 1.77M | |||
| Total Current Liabilities (Q) | 1.67M | |||
| Total Debt (Q) | 482.10K | |||
| Total Liabilities (Q) | 2.05M | |||
| Total Common Equity (Q) | -277.00K | |||
| Cash Flow | BRAXF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -11.40K | |||
| Cash from Financing (TTM) | 880.40K | |||
| Net Change in Cash (TTM) | -1.01M | |||
| Levered Free Cash Flow (TTM) | -718.20K | |||
| Cash from Operations (TTM) | -1.91M | |||
